Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

F4/Atlas Venture/Activity

Atlas Venture Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

Portfolio company Caldera Therapeutics agreed to a reverse merger with Synlogic and a $278M concurrent private placement to reach Nasdaq as CALD.

Caldera Therapeutics

Caldera TherapeuticsAtlas Venture

businesswire.comJUL 29, 2026

JUL 29, 2026

Essay

Atlas Venture principal Aimee Raleigh published an essay on aligning incentives between VCs and biotech operators.

Two Roads Diverged

Atlas Venture

lifescivc.comJUN 30, 2026

JUN 30, 2026

Exit

Portfolio company Remix Therapeutics agreed to a reverse merger with Passage Bio and a $100M private placement to reach Nasdaq as RMTX.

Remix Therapeutics

Remix Therapeutics Atlas Venture

endpoints.newsJUN 25, 2026

JUN 25, 2026

Exit

Portfolio company Antares Therapeutics was acquired by Novartis for up to $1.9B to advance precision oncology programs.

Antares Therapeutics

Antares Therapeutics Atlas Venture

pharmaceutical-technology.comJUN 24, 2026

JUN 24, 2026

Essay

Atlas analysis on life sciences as a segment of broader venture funding landscape amid AI/ML funding concentration.

Stay Humble: Life Sciences as a Small Slice of an Increasingly Big Venture Pie

Atlas Venture

lifescivc.comAPR 23, 2026

APR 23, 2026

Milestone

Portfolio company Kailera Therapeutics completed IPO raising $625M, one of biotech's biggest-ever offerings.

Kailera Therapeutics

Kailera TherapeuticsAtlas Venture

biopharmadive.comAPR 17, 2026

APR 17, 2026

Milestone

Portfolio company Obsidian merged with Galera Therapeutics and secured $350M concurrent private placement to advance TIL cell therapy programs.

Obsidian Therapeutics

Obsidian TherapeuticsAtlas Venture

businesswire.comAPR 14, 2026

APR 14, 2026

Essay

Bruce Booth outlines 2026 biotech predictions including anticipated IPO wave and clinical opportunities ahead.

Chaos is a Ladder: Predictions for 2026

Atlas Venture

lifescivc.comJAN 7, 2026

JAN 7, 2026

Investment

Participated in TRIANA Biomedicines' oversubscribed $120M Series B financing to advance its molecular glue degrader pipeline.

TRIANA Biomedicines

TRIANA Biomedicines Atlas Venture

businesswire.comDEC 3, 2025

DEC 3, 2025

Investment

Participated as an existing investor in Lifordi Immunotherapeutics' $112M round alongside a new Sanofi Ventures strategic investment.

Lifordi

Lifordi Atlas Venture

biospace.comNOV 18, 2025

NOV 18, 2025

Exit

Portfolio company Akero Therapeutics acquired by Novo Nordisk for $4.7B to expand MASH treatment portfolio.

Akero Therapeutics

Akero Therapeutics Atlas Venture

globenewswire.comOCT 9, 2025

OCT 9, 2025

New Fund

Closed Opportunity Fund III with $400M to provide growth capital for existing portfolio companies.

Opportunity Fund III

Atlas Venture

biopharmadive.comSEP 4, 2025

businesswire.com

SEP 4, 2025

Investment

Co-led Antares Therapeutics' $177M Series A for precision oncology medicines.

Antares Therapeutics

Antares Therapeutics Atlas Venture

businesswire.comJUN 10, 2025

JUN 10, 2025

Exit

Portfolio company Sionna went public on NASDAQ, raising $765M for melanoma and cancer immunotherapies.

Sionna

SionnaAtlas Venture

nasdaq.comFEB 2025

FEB 2025

Atlas Venture | Activity | F4